Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 25

1.

Biomarkers for antipsychotic therapies.

Pich EM, Vargas G, Domenici E.

Handb Exp Pharmacol. 2012;(212):339-60. doi: 10.1007/978-3-642-25761-2_13. Review.

PMID:
23129338
[PubMed - indexed for MEDLINE]
2.

Transcription and pathway analysis of the superior temporal cortex and anterior prefrontal cortex in schizophrenia.

Barnes MR, Huxley-Jones J, Maycox PR, Lennon M, Thornber A, Kelly F, Bates S, Taylor A, Reid J, Jones N, Schroeder J, Scorer CA, Davies C, Hagan JJ, Kew JN, Angelinetta C, Akbar T, Hirsch S, Mortimer AM, Barnes TR, de Belleroche J.

J Neurosci Res. 2011 Aug;89(8):1218-27. doi: 10.1002/jnr.22647. Epub 2011 Apr 27.

PMID:
21538462
[PubMed - indexed for MEDLINE]
3.

ADAMTSL3 as a candidate gene for schizophrenia: gene sequencing and ultra-high density association analysis by imputation.

Dow DJ, Huxley-Jones J, Hall JM, Francks C, Maycox PR, Kew JN, Gloger IS, Mehta NA, Kelly FM, Muglia P, Breen G, Jugurnauth S, Pederoso I, St Clair D, Rujescu D, Barnes MR.

Schizophr Res. 2011 Apr;127(1-3):28-34. doi: 10.1016/j.schres.2010.12.009. Epub 2011 Jan 15.

PMID:
21239144
[PubMed - indexed for MEDLINE]
4.

Adenoviral-mediated Cre expression effectively suppresses GlyT1 binding in the thalamic area of GlyT1 conditional knock-out mice.

Cazzin C, Zanderigo F, Costantini VJ, Zambello E, Ring CJ, Morrison AD, Caberlotto L, Kew JN.

J Neurosci Methods. 2010 Nov 30;193(2):254-63. doi: 10.1016/j.jneumeth.2010.09.001. Epub 2010 Sep 9.

PMID:
20832426
[PubMed - indexed for MEDLINE]
5.

A short primer on the functional analysis of copy number variation for biomedical scientists.

Barnes MR, Breen G.

Methods Mol Biol. 2010;628:119-35. doi: 10.1007/978-1-60327-367-1_7. Review.

PMID:
20238079
[PubMed - indexed for MEDLINE]
6.

Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections.

Domenici E, Willé DR, Tozzi F, Prokopenko I, Miller S, McKeown A, Brittain C, Rujescu D, Giegling I, Turck CW, Holsboer F, Bullmore ET, Middleton L, Merlo-Pich E, Alexander RC, Muglia P.

PLoS One. 2010 Feb 11;5(2):e9166. doi: 10.1371/journal.pone.0009166.

PMID:
20161799
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics.

Dawson LA, Langmead CJ, Dada A, Watson JM, Wu Z, de la Flor R, Jones GA, Cluderay JE, Southam E, Murkitt GS, Hill MD, Jones DN, Davies CH, Hagan JJ, Smith PW.

Eur J Pharmacol. 2010 Feb 10;627(1-3):106-14. doi: 10.1016/j.ejphar.2009.10.054. Epub 2009 Oct 30.

PMID:
19879867
[PubMed - indexed for MEDLINE]
8.

Analysis of gene expression in two large schizophrenia cohorts identifies multiple changes associated with nerve terminal function.

Maycox PR, Kelly F, Taylor A, Bates S, Reid J, Logendra R, Barnes MR, Larminie C, Jones N, Lennon M, Davies C, Hagan JJ, Scorer CA, Angelinetta C, Akbar MT, Hirsch S, Mortimer AM, Barnes TR, de Belleroche J.

Mol Psychiatry. 2009 Dec;14(12):1083-94. doi: 10.1038/mp.2009.18. Epub 2009 Mar 3. Erratum in: Mol Psychiatry. 2010 Apr;15(4):442-3. Mol Psychiatry. 2009 Dec;14(12):1146. Akbar, T [corrected to Akbar, M T].

PMID:
19255580
[PubMed - indexed for MEDLINE]
9.

Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice.

Woolley ML, Carter HJ, Gartlon JE, Watson JM, Dawson LA.

Eur J Pharmacol. 2009 Jan 28;603(1-3):147-9. doi: 10.1016/j.ejphar.2008.12.020. Epub 2008 Dec 16.

PMID:
19111716
[PubMed - indexed for MEDLINE]
10.

Investigation of G72 (DAOA) expression in the human brain.

Benzel I, Kew JN, Viknaraja R, Kelly F, de Belleroche J, Hirsch S, Sanderson TH, Maycox PR.

BMC Psychiatry. 2008 Dec 11;8:94. doi: 10.1186/1471-244X-8-94.

PMID:
19077230
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Population-based linkage analysis of schizophrenia and bipolar case-control cohorts identifies a potential susceptibility locus on 19q13.

Francks C, Tozzi F, Farmer A, Vincent JB, Rujescu D, St Clair D, Muglia P.

Mol Psychiatry. 2010 Mar;15(3):319-25. doi: 10.1038/mp.2008.100. Epub 2008 Sep 16.

PMID:
18794890
[PubMed - indexed for MEDLINE]
12.

Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1.

Langmead CJ, Austin NE, Branch CL, Brown JT, Buchanan KA, Davies CH, Forbes IT, Fry VA, Hagan JJ, Herdon HJ, Jones GA, Jeggo R, Kew JN, Mazzali A, Melarange R, Patel N, Pardoe J, Randall AD, Roberts C, Roopun A, Starr KR, Teriakidis A, Wood MD, Whittington M, Wu Z, Watson J.

Br J Pharmacol. 2008 Jul;154(5):1104-15. doi: 10.1038/bjp.2008.152. Epub 2008 May 5.

PMID:
18454168
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity.

Woolley ML, Pemberton DJ, Bate S, Corti C, Jones DN.

Psychopharmacology (Berl). 2008 Feb;196(3):431-40. Epub 2007 Dec 5.

PMID:
18057917
[PubMed - indexed for MEDLINE]
14.

Comparison between intraperitoneal and subcutaneous phencyclidine administration in Sprague-Dawley rats: a locomotor activity and gene induction study.

Kalinichev M, Robbins MJ, Hartfield EM, Maycox PR, Moore SH, Savage KM, Austin NE, Jones DN.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):414-22. Epub 2007 Sep 16.

PMID:
17945407
[PubMed - indexed for MEDLINE]
15.

The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection.

Corti C, Battaglia G, Molinaro G, Riozzi B, Pittaluga A, Corsi M, Mugnaini M, Nicoletti F, Bruno V.

J Neurosci. 2007 Aug 1;27(31):8297-308.

PMID:
17670976
[PubMed - indexed for MEDLINE]
Free Article
16.

Altered dimerization of metabotropic glutamate receptor 3 in schizophrenia.

Corti C, Crepaldi L, Mion S, Roth AL, Xuereb JH, Ferraguti F.

Biol Psychiatry. 2007 Oct 1;62(7):747-55. Epub 2007 May 24.

PMID:
17531207
[PubMed - indexed for MEDLINE]
17.

Evaluation of the mGlu8 receptor as a putative therapeutic target in schizophrenia.

Robbins MJ, Starr KR, Honey A, Soffin EM, Rourke C, Jones GA, Kelly FM, Strum J, Melarange RA, Harris AJ, Rocheville M, Rupniak T, Murdock PR, Jones DN, Kew JN, Maycox PR.

Brain Res. 2007 Jun 4;1152:215-27. Epub 2007 Mar 15.

PMID:
17434465
[PubMed - indexed for MEDLINE]
18.

The common inositol-reversible effect of mood stabilizers on neurons does not involve GSK3 inhibition, myo-inositol-1-phosphate synthase or the sodium-dependent myo-inositol transporters.

Di Daniel E, Cheng L, Maycox PR, Mudge AW.

Mol Cell Neurosci. 2006 May-Jun;32(1-2):27-36. Epub 2006 Mar 13.

PMID:
16531065
[PubMed - indexed for MEDLINE]
19.

5-ht5A receptors as a therapeutic target.

Thomas DR.

Pharmacol Ther. 2006 Sep;111(3):707-14. Epub 2006 Mar 6. Review.

PMID:
16516972
[PubMed - indexed for MEDLINE]
20.

Dopamine D2 and D3 receptor agonists limit oligodendrocyte injury caused by glutamate oxidative stress and oxygen/glucose deprivation.

Rosin C, Colombo S, Calver AA, Bates TE, Skaper SD.

Glia. 2005 Dec;52(4):336-43.

PMID:
16078234
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk